Certified statement

My name is Oscar Hernandez. I am Director of the Risk Assessment Division (RAD), Office of Pollution Prevention and Toxics (OPPT), United States Environmental Protection Agency.

The Agency has received two communications from Robert A. Bilott (R. Bilott), Esq., which include "the results of PFOA serum testing performed through DuPont and its contractor, Exygen, for twelve members of the general population living near DuPont's Washington Works facility in Wood County, WV." (Attachment 1).

These are the first results we have seen from sampling of serum from individuals exposed in a community setting. This information is not corroborative of information already documented in the published scientific literature or otherwise available to the Agency. These new data are particularly useful because they represent an attempt to associate body burden in the general population with a specific exposure pathway and a source of exposure. Serum levels in the 12 individuals studied ranged from 15.7 to 128 ppb, with a mean of 67 ppb. The mean general population level reported to the Agency is estimated to be approximately 5 ppb APFO/PFOA in serum.

DuPont was required to report this information under the authority of TSCA §8(e) subsequent to the company's receipt of the serum results from their contractor, Exygen. Based on documents provided by R. Bilott (Attachment 1), that information was received by DuPont by August 5, 2004. A review (Attachment 2), carried out on September 30, of TSCA §8(e) and other TSCA reports indicated that DuPont has not submitted these data to the Agency. Thus, the Administrator was not adequately informed at the time the results were obtained by DuPont nor subsequent to that time.

Oscar Hernandez, Director (7403M)

Date: Ochler 7, ZOV4

Risk Assessment Division/OPPT

Attachments (2)

Attachment 1

TAFT, STETTINIUS & HOLLISTE..LLP

NORTHERN KENTUCKY OFFICE SUITE 340 1717 DIXIE HIGHWAY COVINGTON, KENTUCKY 41011-4704 606-331-2838 513-381-2838 FAX: 513-381-6613

> DAYTON, OHIO OFFICE SUITE 900 110 NORTH MAIN STREET DAYTON, OHIO 45402-1786 937-228-2838 FAX: 937-228-2816

425 WALNUT STREET, SUITE 1800 CINCINNATI, OHIO 45202-3957

513-381-2838 FAX: 513-381-0205

www.taftlaw.com

CLEVELAND, OHIO OFFICE 3500 BP TOWER 200 PUBLIC SQUARE CLEVELAND, OHIO 44114-2302 216-241-2838 FAX: 216-241-3707

COLUMBUS, OHIO OFFICE 21 EAST STATE STREET COLUMBUS, OHIO 43215-4221 614-221-2838 FAX:614-221-2007

ROBERT A. BILOTT (513) 357-9638 bilott@taftlaw.com

September 15, 2004

Dr. Charles M. Auer (7405M) USEPA 1200 Pennsylvania Avenue, N.W. Washington, DC 20460

Mary Ellen Weber (7406M) USEPA 1200 Pennsylvania Avenue, N.W. Washington, DC 20460

Mary Dominiak (7405M) USEPA 1200 Pennsylvania Avenue, N.W. Washington, DC 20460 Oscar Hernandez (7405M) USEPA 1200 Pennsylvania Avenue, N.W. Washington, DC 20460

Jennifer Seed (7403M) USEPA 1200 Pennsylvania Avenue, N.W. Washington, DC 20460

Re:

PFOA-Exposed Community Blood Sample Results

(For AR-226 And OPPT-2003-0012)

Ladies and Gentlemen:

In response to USEPA's previous requests for information relating to the threat to human health and the environment involving PFOA/C-8, we have enclosed the results of PFOA serum testing performed through DuPont and its contractor, Exygen, for twelve members of the general population living near DuPont's Washington Works facility in Wood County, WV. All twelve of the individuals tested have been exposed to PFOA/C-8 through drinking water provided by the Lubeck Public Service District where, according to DuPont, the level of PFOA/C-8 in the drinking water has averaged approximately 0.5 ppb over the last several years. These individuals also claim to have stopped using the contaminated public drinking water as their primary source of drinking water approximately three years ago, and switched to alternative sources, such as bottled water. Only one of the individuals (with a PFOA serum result of 90.4 ppb) ever worked

Dr. Charles M. Auer Oscar Hernandez Jennifer Seed Mary Ellen Weber Mary Dominiak September 15, 2004 Page 2

at the DuPont Washington Works Plant. A chart summarizing the results from the enclosed lab report (EID871401-10) is presented below. Please include this information in AR-226 and OPPT-2003-0012.

<u>SEX</u>	<u>AGE</u>	PFOA SERUM (PPB)	APPROX. YEARS ON WATER
		> 1	
F	55	128	>20
M	52	103/103	>20
M	70	90.4	>20
F	80	83.1	10-20
M	63	78.5/73.7	10-20
F	46	65	5-10
M	69	61.3	<5
M	36	56.4/50.8	>20
M	57	51.2	10-20
F	. 55	42.6	10-20
F	48	40.1	10-20
M	57	15.7	<5

Very truly yours,

Robert A. Bilott

RAB/mdm Enclosure Dr. Charles M. Auer Oscar Hernandez Jennifer Seed Mary Ellen Weber Mary Dominiak September 15, 2004 Page 3

cc: R. Edison Hill, Esq. (w/o encl.)
Larry A. Winter, Esq. (w/o encl.)
Gerald J. Rapien, Esq. (w/o encl.)



Analytical Report

Occupational and Environmental Health

Analysis of Perfluorocctanoic Acid (PFOA) in Human Serum Samples

Exygen Report No. L0003000

Testing Laboratory

Exygen Research 3058 Research Drive State College, PA 16801

Requester

Dr. Marsha Bailey
Occupational and Environmental Health
4 Rosemar Circle
Farkersburg, WV 26101
(304)-757-0270

EID871401

PAGE 1 CF4

3058 Research Drive State College, PA 16801, USA T: 800.281.3219 F: 814.272.1019

Time	%A	%B		Flow Rate (mL/n	nin)
0.0	40	60		0.3	
3.0	40	60		. 0.3	
3.5	0	100		0.3	
3.7	0	100		0.5	
7.0	0	100		0.5	
7.5	40	60	-	0.5	
9.0	40	60		0.5	
9.5	40	60		0.3	
12.0	40	60		0.3	

The following parameters were used for operation of the mass spectrometer:

Parameter	Setting
Ionization Mode	Electrospray
Polarity	Negativa
Transitions Monitored	413->369 (PFOA), 415->370 (12C-PFOA)
Gas Temperature	350°C
Drying Gas (N2)	7.0 L/min



4.1 Calibration

A 6-point calibration curve was analyzed throughout the analytical sequence for the fluorocompounds. The calibration points were prepared at 0.5, 1, 5, 10, 20, 50 ng/mL for PFOA. The instrument response versue the concentration was plotted for each point. Using linear regression with 1/x weighting, the slope, y-intercept and coefficient of determination (r) were determined. A calibration curve is acceptable if $r^2 \geq 0.985$.

.... For the results reported here, calibration criteria were met.

4.2 Surrogates

Surrogate spikes were not a part of this analysis.

4.3 Laboratory Control Spikes

Laboratory control spikes in the analytical set were prepared by adding a known concentration of the analytes to control human serum. Laboratory control spikes are used to assess method accuracy. The laboratory control spikes must show recoveries between 80-120% for levels at the LOQ and 85-115% for levels greater than the LOQ or the data is rejected. For the results reported here, the spikes were within the acceptable range.

4.4 Matrix Spikes

Two matrix spikes in the analytical set were prepared by adding a known concentration of the target analyte to separate human serum samples. Matrix spikes are used to assess method accuracy in the matrix. The matrix spikes should show recoveries between 85-115%. For the results reported here, the matrix spikes were within the acceptable range.

4.5 Sample Related Comments

Three samples in the analytical set were extracted and analyzed in duplicate. Duplicate sample results are reported along with the sample results in Attachment B.

5 Data Summary

Please see Attachment B for a detailed listing of the analytical results. Results are reported in parts per billion (ng/mL) for the analytes on an as-received basis.

6 Data/Sample Retendion

Samples are disposed of one month after the report is issued unless otherwise specified. All electronic data is archived on retrievable media and hard copy reports are stored in data folders maintained by Exigen. Hardcopy data is stored for a minimum of five years. Occupational and Environmental Health will be notified 30 days prior to the disposal of hardcopy data.

- 7 Attachments
- 7.1 Attachment A: Chain of Custody
- 7.2 Attachment B: Analytical Results
- 8 Signaturas

Entry R. Sector, Principal Investigator	7/29/04	
Ernay R. Gecther, Principal Investigator	Data	~
al m Flehous	7/29/04	
John M. Fisherty, Vice President	Date	

PAGE 4 OF 4

EID871404



3058 Research Drive State College, PA 16801

Phone: 814-272-1039 Fax: 814-231-1580

Conform COC Sample: True
Conform COC: True
Conform Sample: True
Conform Request True

Login Group: L0003000

Login #:

3110

Project

P0000959

Company Name: DuPont de Nemours & Co, Inc.

Submitted By:

Charles R. Powley

Login Type:

Immediate Receipt of Samples

Started: Date Start

07/23/2004 08/05/2004

Due Date: Received Date:

07/23/2004

Received By: Spread Sample: Ammerman, Mark

Label:
Exygen SD/PI: Decker, Emily
Project Title/Type: Analysis for PFOA in Human Serum Samples by LC/MS/MS / ROUTINE

Login Notes: Conform Notes:

Packag	es / Cor	tainers

	•		Pack	ages / Containers	3			
Package	Carton	Mall Date	/ Condition	Shipport ID		Tem	p, Control/Temp,	Direction / Handled By :
PK0003722	Package		3:38:30PM Uncompremised	FEDEX 8458 8093 4889			Dry Ice .: :	RECEIVED Ammerman, Mark
Container#	Gross Weight	pН	Container Type	Preservative			Mfg. Lot	Mfg_ID
C0040826	4.00 g		5 ml serum tuba	NONE				
C0040828	4.40 g		5 ml serum tube	NONE		•	•	
C0040829	4.70 g		5 ml secum tubo	NONE	8	•		·
C0040831	4.80 g		5 ml serum tube	NONE			10.	
C0040834	4.80 g		5 ml serum tubo	NONE				
C0040836	4.50 g		5 ml sorum tube	NONE				
C0040839	4.80.9		5 mt serum tube	NONE				
C0040841	4.60g		5 ml serven tube	NONE	-	***		
C0040843	5.00 g		5 ml sarum tubo	NONE		*	-	
C0040844	4.80 g		5 ml serum tube"	NONE				•
C0040845	5.30 g		5 ml serum tube	NONE				•
C0040848	4.00 g		5 mi serum tubo	NONE				

EID871405

7/29/04 Login.rpt Report Version: Jul 14 2004 11:35AM . Page 1 of 2

Instance: -

R0113316 DE LE DES DE CONTRACTOR DE LA CONTRACTOR

400111

				Sai	mples				
Sample ID Lp003000-0001	Container	MSILE WSILE	Fraction Human Sarum	Sample		= 90	Data Sample 07/22/2004	07/23/2004	09/00/5004 Date Drie
	C0040826								
F0003000-0003	C0040828	LIQUID	Human Serum	:		CONFIDENTIAL	07/22/2004	07/23/2004	08/06/5004
L0003000-0003	C0040829	riguio	Human Serum	•		INFORMATION	07/22/2004	07/23/2004	08/06/2004
L0003000-0004	C0040831	מוטסנו	Human Serum			REDACTED	07/22/2004	07/23/2004	08/06/2004
L0003000-0005	C0040834	LIOUID	Human Serum		•		07/22/2004	07/23/2004	06/06/2004
L0003000-0006	C0040838	LIQUID	Human Sarum				07/22/2004	07/23/2004	08/06/2004
L0003000-0007	C0040839	LIQUID	Human Sarum	* * * * * * * * * * * * * * * * * * *	•		07/22/2004	07/23/2004	08/06/2004
LD003000-0008	C0040841	rianio	Human Sarum	i.			07/22/2004	07/23/2004	08/06/2004
L0003000-0009	C0040843	riguip	Human Serum		•	,	07 <i>F22/</i> 2004	07/23/2004	06/06/2004
L0003000-0010	C0040844	มดบเอ	Human Serum	*		. *	07/22/2004	07/23/2004	08/06/2004
L0003000-0011	C0040845	: LIQUID	Human Serum	•	••		· 07/22/2004	07/23/2004	08/06/2004
L0003000-0012	C0040845		Human Sarum	v	:		07/22/2004	07/23/2004	02/06/2004

EID871406

7/29/04 Login.rpt Report Version: Jul 14 2004 11:35AM . . Page 2 of 2

Instance: '.

R0113316 |趣]底質型型包配

CHAIN OF CUSTODY Exygen Research Sample Receiving • 3048 Research Drive • State College, PA 16801 T. 814.231.8032 • www.exygenresearch.com FAX: 814.231.1580

COLLECTION SITE IN	FORMATION	STAFF INVOLV	'ED IN ŞAMP	LE SHIPME	NT .
Collection Site (name & add		1. Logh Hor	o Painter		
Dr. Dbrshar	xiley	(Printed Name)	Diche	CY'P	7.2264
Fy roseme	Circle	Sprettire	Muller		itials/Date
Larbershurg, L	10116 NO	2. Terrila	Thevenin		
-		(Printed Name)	Thomas	, 77	70001
7		Slovabura (Mewner		7.33.04 itaalyDate
Phone: 04-75	7-0070	3			
	-0913	(Printed Name)			:.
Email: MDileijoe	h avenzon net	Sgnature		- Inl	tlah/Date
IMPORTANT: Each person wh	o enters information on	this form must add th	neir name, signat	ure, initials, an	d date
Ishme Line out unixed prom	mte Snarth, AM or PM for	ime entries Include m	onth day and wea	fordates Con	tents of
padage must be verified by so prompt.(*) Thoroughly docu	meone other than the p ment the reason for any til	ackager; attest to tr	ne vermcation by time the serum t	reparation is c	cating the
and the time packaged by ac	ding a footnote to the b	ottom of the page.		3	
Sample I	dentification .	-Blood Saint	ile Collection Se	rum Sample Pre Date & T	p. Completed
	3 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	יונא בב. ד	CO COMPONION		1:3500
THE PROPERTY ON		7.22.04	9:55 un	143.CG.CT.	ลารอก
ONFIDENTIAL INFORMATION		7:2064	13:20 Pm	7.20.04	1:56pm
EDACTED		7.20.04	11:00an	7.22-04	12:17 Dm
Nr. 2		7.20.04	:10:45an	7.2204	1:547m
ļ.		7.20.04	10:00	7.2004	1:47 pin
. .	-	J-3244	15.0254	7.35.04	1:45217
		7.2004	10:35	7.2204	9:38 DW
} .		7.25.09	11:2000	1.,35-07	1 2:23 pm
-		7 22.04	1 8.00m	7.550	11:38:pm
}		7.20.74	18:20cm	1) 22.C	11:30 Pm
} -		7.0017	0.00	1.750	TINON
		•			
PLEASE FAX THE COMPLETED F	ORM to Bygen Sample Receiv	ing Cooler Cont	ents Verified	» — -	
prior to shipping samples.			nitial & Date"	1 141	115510A
KEEP THE PINK COPY and include th	THE RESERVE THE PROPERTY OF THE PERSON NAMED IN COLUMN TWO PERSONS NAMED IN COLUMN TRANSPORT NAMED IN COLUMN T	Constitution of the last of th		The Property Property and Inc.	THE CALL WATER WOMEN
Relinquished by	Date Time	Received by	27 No.	Date	Time
-		11-/-		107/27kg	Alo.
Note: When samples arrive at Boygen, chain-	of-autody procedures follow Exve	an SOP V401, "Contract Re-	search Samole Harvien	r Page	of 1
		,		- 0	REX 1. 1 1, 03
		3. - 0.			107

ELDO OSTA	Sign College DA Blogg	Extiden processing and 361.7518 Summan Extiden processing and 361.7518 Summan Extiden processing and 361.7518	Ocupation Landinary al Hallh	LOCC. D. S. O. O. O. C.
The states that a Disposition per dates is Plant that the form. 8 Reliance Disposition Approximate the state of the state	Trymond and Company Co	Feeding browning Const. Const.	Control State Stat	A Committee Comm



Summary of Residue Found (ng/mL) for PFOA in Human Serum Samples

1	•
Sponsor ID	PFOA (ppb)
10	
	- 103
`	103
	65.0
CONFIDENTIAL INFORMATION	15.7
*	E.13
REDACTED	90.4
,	55.4
•	50.8
	40.1
¥	128
,	51.2
	83.1
•	73.7
	78.5
	42.6

EID871409

: 814,272,1639 F: 814,231,1580 exygen.com





Summary of Recoveries (%) for PFOA in Human Serum Samples

Sponsor	PFOA (ppb)	Amount Fortified (ppb)	Recovery (%)	
	. 5.10	5.0	102	
CONFIDENTIAL INFORMATION	16.2	10	107	
	1040	1040 1000		
REDACTED	1090	1000	88	••
	4590	8000	90	••
		AVERAGE:	100	
		STD DEV:	6.4	
\		% RSD:	6.4	

Summary of RFOA (ng/mL) In Human Serum Control Samples

Sponsor ID	/	PFOA (ng/mL)
Control A	1	5.47

EID871410

3058 Research Drive Scare Codegs, Pt. 16801, USA T: 814.272.1039 F: 814.231.1580

STEPTOE & JOHNSON LLP

ATTORNEYS AT LAW

Jennifer Quinn-Barabanov 202.429.8027 jquinnba@steptoe.com

1330 Connecticut Avenue, NW Washington, DC 20036-1795
Tel 202.429.3000
Fax 202.429.3902
steptoe.com

August 5, 2004

VIA FACSIMILE
R. Edison Hill, Esquire
Hill, Peterson, Carper, Bee & Deitzler, PLLC
NorthGate Business Park
500 Tracy Way
Charleston, WV 25311-1261

Re: Jack W. Leach, et al. v. E. I. du Pont de Nemours and Company

Circuit Court of Wood County, WV, Civil Action No. 01-C-608

Dear Ed:

REDACTED

WASHINGTON

PHOENIX

LOS ANGELES

LONDON

BRUSSELS

R. Edison Hill, Esquire August 5, 2004 Page 2

REDACTED

Enclosed please find Exygen's Analytical Report of C-8 in the blood samples provided by

REDACTED

R. Edison Hill, Esquire August 5, 2004 Page 3

REDACTED

Sincerely,

Jennifer Quinn-Barabanov

Encl.

cc: Robert A. Bilott, Esquire

Larry A. Winter, Esquire Heather Heiskell Jones, Esquire

Douglas J. Simmons, Esquire

Diana Everett, Esquire

STEPTOE & JOHNSON LLP

Jennifer Quinn-Barabanov 202429.8027 jquinnba@steptoe.com 1330 Cionnecticut Avenue, NW Washington, DC 20036-1795 Tel 202.429.3000 Fax 202.429.3902 sceptoe.com

August 13, 2004

VIA FACSIMILE
Robert A. Bilott, Esquire
TAFT, STETTINIUS & HOLLISTER LLP
425 Walnut Street, Suite 1800
Cincinnati, Ohio 45202-3957

Re: Jack W. Leach, et al. v. E. I. du Pont de Nemours and Company Circuit Court of Wood County, WV, Civil Action No. 01-C-608

Dear Rob:

This letter responds to your electronic mail message of yesterday concerning DuPont's designation of the results of the Exygen Analytical Report set forth at EID8171409 as confidential.

DuPont stamped this document confidential, in accordance with the terms of the protective order.

REDACTED

the document was designated confidential to protect the privacy of REDACTED. As a result, the confidential designation is proper.

I have no objection to lifting the designation, however, if you provide a specific written request to remove the designation, along with proposed reductions, and make an express representation that you are authorized to seek removal of the confidential designation

REDACTED

Since cely,

jennifer Quinn-Barabanov

anallum /

Robert A. Bilott, Esquire August 13, 2004
Page 2

ce: R. Edison Hill, Esquire
Larry A. Winter, Esquire
Heather Heiskell Jones, Esquire
Douglas J. Simmons, Esquire
Diana Everett, Esquire

1 AFT, STETTINIUS & HOLLISTER LL.

NORTHERN KENTUCKY OFFICE SUITE 340 1717 DIXIE HIGHWAY COVINGTON, KENTUCKY, 41011-4704 606-331-2838 513-381-2838 FAX: 513-381-8613

> DAYTON, OHIO OFFICE SUITE 900 110 NORTH MAIN STREET DAYTON, OHIO 45402-1786 937-228-2838 FAX: 937-228-2818

425 WALNUT STREET, SUITE 1800 CINCINNATI, OHIO 45202-3957

513-381-2838 · FAX: 513-381-0205

www.taftlaw.com

CLEVELAND, OHIO OFFICE 3500 BP TOWER 200 PUBLIC SQUARE CLEVELAND, OHIO 44114-2302 216-241-238 FAX: 216-241-3707

COLUMBUS, OHIO OFFICE 21 EAST STATE STREET COLUMBUS, OHIO 43215-4221 814-221-2838 FAX:614-221-2007

. Bilott Inda

ROBERT A. BILOTT 513-357-9638 bilott@taftlaw.com

August 13, 2004

VIA TELECOPY

Jennifer Quinn-Barabanov, Esq. Steptoe & Johnson LLP 1330 Connecticut Avenue, NW Washington, DC 20036-1795

Re.

Jack W. Leach, et al. v. E.I. duPont de Nemours and Company (Circuit Court of Wood Cty, WV, Civil Action No. 01-C-608)

Dear Jennifer:

In response to your letter of August 13, 2004, we again repeat our request, as set forth in my e-mail to you from yesterday, that DuPont produce a non-confidential, redacted version of the Exygen Report (EID8171409) which omits the information you reference in your letter as revealing personal identifying information **REDACTED** Please produce the redacted version removing any information DuPont believes reveals personal identifying information as soon as possible.

Very truly yours,

Robert A. Bilott

RAB:mdm

cc.

Heather Heiskell Jones, Esq.

R. Edison Hill, Esq. Larry A. Winter, Esq. Gerald J. Rapien, Esq. 1AFT, STETTINIUS & HOLLISTER LLP

NORTHERN KENTUCKY OFFICE SUITE 340 1717 DIXIE HIGHWAY COVINGTON, KENTUCKY 41011-4704 606-331-2838 513-381-2838 FAX: 513-381-6613

> DAYTON, OHIO OFFICE SUITE 900 110 NORTH MAIN STREET DAYTON, OHIO 45402-1786 937-228-2838 FAX: 937-228-2816

425 WALNUT STREET, SUITE 1800 CINCINNATI, OHIO 45202-3957

513-381-2838 FAX: 513-381-0205

www.taftlaw.com

CLEVELAND, OHIO OFFICE 3500 BP TOWER 200 PUBLIC SQUARE CLEVELAND, OHIO 44114-2302 216-241-2038 FAX: 216-241-3707

COLUMBUS, OHIO OFFICE 21 EAST STATE STREET COLUMBUS, OHIO 43215-4221 614-221-2838 FAX:614-221-2007

ROBERT A. BILOTT 513-357-9638 bilott@taftlaw.com

August 17, 2004

VIA TELECOPY

Jennifer Quinn-Barabanov, Esq. Steptoe & Johnson LLP 1330 Connecticut Avenue, NW Washington, DC 20036-1795

Re:

Jack W. Leach, et al. v. E.I. duPont de Nemours and Company

(Circuit Court of Wood Cty, WV, Civil Action No. 01-C-608)

Dear Jennifer:

Pursuant to your request, we have attached a copy of the Exygen report produced by DuPont that DuPont had stamped in its entirety as "confidential" under the Stipulated Protective Order, as modified, in this case (EID871401-10), with all personal identifying information redacted. Plaintiffs do not believe that this redacted version of the document, which does not contain any personal identifying information, should be marked "confidential" under the Stipulated Protective Order, as modified. Please confirm whether DuPont believes that any portion of the attached redacted version of the document should be marked "confidential" under the terms of the Stipulated Protective Order, as modified, and whether DuPont will agree to withdraw its confidentiality claim over the redacted version of the attached document.

Very truly yours,

buit a. Bilott/mdn

Robert A. Bilott

RAB:mdm Attachment Jennifer Quinn-Barabanov, Esq. August 16, 2004 Page 2

cc: Heather Heiskell Jones, Esq. (w/ attachment)
R. Edison Hill, Esq. (w/ attachment)

R. Edison Hill, Esq. (w/ attachment)
Larry A. Winter, Esq. (w/ attachment)
Gerald J. Rapien, Esq. (w/ attachment)

STEPTOE & JOHNSON W

ATTORNEYS AT LAW

Jennifer Quinn-Barabanov 202.429.8027 jquinnba@steptoe.com 7330 Connecticut Avenue, NW Washington, DC 20036-1795 Tel 202.429.3000 Fax 202.429.3902 steptoe.com

August 27, 2004

VIA FACSIMILE

Robert A. Bilott, Esquire TAFT, STETTINIUS & HOLLISTER LLP 425 Walnut Street, Suite 1800 Cincinnati, Ohio 45202-3957

Re:

Jack W. Leach, et al. v. E. I. du Pont de Nemours and Company Circuit Court of Wood County, WV, Civil Action No. 01-C-608

Dear Rob:

Enclosed please find a copy of the Exygen Analytical Report, EID871401-EID871410, that has been redacted as you requested. Based on the representation in your August 17, 2004 letter that you do not believe that the document with your redactions contains any personally identifiable information that would make it appropriate for confidential designation under the Stipulated Protective Order, we have withdrawn the confidential designation for this document.

Thank you.

Sincerely,

Jennifer Quinn-Barabanov

Encl.

Robert A. Bilott, Esquire August 27, 2004 Page 2

cc: R. Edison Hill, Esquire
Larry A. Winter, Esquire
Heather Heiskell Jones, Esquire
Douglas J. Simmons, Esquire
Diana Everett, Esquire

Robert A. Bilott, Esquire August 27, 2004 Page 3

bcc: John R. Bowman, Esquire

Silvio J. DeCarli, Esquire Ms. Marie Thompson

Laurence F. Janssen, Esquire Stephen A. Fennell, Esquire Libretta P. Stennes, Esquire



Analytical Report

Occupational and Environmental Health

Analysis of Perfluorooctanoic Acid (PFOA) in Human Serum Samples

Exygen Report No. L0003000

Testing Laboratory

Exygen Research 3058 Research Drive State College, PA 16801

Requester

Dr. Marsha Bailey
Occupational and Environmental Health
4 Rosemar Circle
Parkersburg, WV 28101
(304)-757-0270

EID871401

PAGE 1 OF 4

3058 Research Drive State College, PA 16801, USA T: 800.281.3219 F: 814.272.1019 exygenresearch.com

1 introduction

Results are reported for the analysis of perfuorocctanolo acid (PFOA) in human serum samples received at Exygen from Dr. Marsha Balley at Occupational and Evironmental Health. The Exygen project number assigned to the samples is P959.

2 Sempla Hackit

A total of twelve samples were received at Exygen in 5 mL screw-cap vials labeled with permanent marker. A copy of all sample log-in information is presented in Attachment A

The twelve samples were received on 07/23/04. The samples were shipped frozen on dry ice via FedEx. The samples were stored frozen from time of receipt until analysis.

3 Melfioda - Analydical and Preparatory

3.1 Sample Preparation

The samples were extracted and analyzed according to the durrent revision of method ExM-008-211. Fifty microfiters of sample was used for the extraction procedure. Using the Multiprobe apparatus, 500 pt. of acetonitrile was added to the sample and then passed through a protein precipitation column.

3.2 Sample Analysis by LC/MS and LC/MS/MS

In High Pressure Liquid Chromatography (HPLC), an aliquot of extract is injected and passed through a liquid-phase chromatographic column. Based on the affinity of the analyse for the stationary phase in the column relative to the liquid mobile phase, the analyse is retained for a characteristic amount of time. Following HPLC separation, mass spectrometry provides a rapid and accurate means for analyzing a wide range of organic compounds. Molecules are ionized, fragmented, and detected. The ions characteristic of the compounds are observed and quantitated against extracted standards.

An HP1100 system interfaced to a PE Sciex API 4000 system was used to analyze the sample extracts. A gradient elution through a Jones Chromatography Genesis C-8 50 x 2.1 mm x 4µm column was used for separation.

The following gradient was performed:

Mobile Phase (A):

2mM Ammonium Acetate in Type I Water

Mobile Phase (B):

Methanol

EID871402

PAGE 2 OF A

Time	%A	%B		Flow	Rate (mL/min)
<u>Time</u> 0.0	40	<u>%B</u> 60			0.3
3.0	40 .	60			0.3
3.5	0	100			0.3
3.7	. 0	100			0.5
7.0	0	100		_	0.5
7.5	40	60	-	-	0.5
9.0	40	60			0.5
9.5	40	60			0.3
120	40	60			0.3

The following parameters were used for operation of the mass spectrometer:

Parameter	Setting
Ionization Mode	Electrospray Necetive
Polarity Transitions Monitored	413->369 (PFOA), 415->370 (13C-PFOA)
Gas Temperature Drying Gas (N2)	350°C 7.0 L/min

A Analysis

4.1 Calibration

A 8-point calibration curve was analyzed throughout the analytical sequence for the fluorocompounds. The calibration points were prepared at 0.5, 1, 5, 10, 20, 50 ng/mL for PFCA. The instrument response versus the concentration was plotted for each point. Using linear regression with 1/x weighting, the slope, y-intercept and coefficient of determination (r) were determined. A calibration curve is acceptable if $r^2 \ge 0.985$.

....For the results reported here, calibration criteria were met.

4.2 Surrogates

Surrogate spikes were not a part of this analysis.

4.3 Laboratory Control Spikes

Laboratory control spikes in the analytical set were prepared by adding a known concentration of the analytes to control human serum. Laboratory control spikes are used to assess method accuracy. The laboratory control spikes must show recoveries between 80-120% for levels at the LOQ and 85-115% for levels greater than the LOQ or the data is rejected. For the results reported here, the spikes were within the acceptable range.

4.4 Matrix Spikes

Two matrix splices in the analytical set were prepared by adding a known concentration of the target analyte to separate human serum samples. Matrix splikes are used to assess method accuracy in the matrix. The matrix splikes should show recoveries between 85-115%. For the results reported here, the matrix splikes were within the acceptable range.

4.5 Sample Related Comments

Three samples in the analytical set were extracted and analyzed in duplicate. Duplicate sample results are reported along with the sample results in Attachment B.

5 Data Summary

Please see Attachment B for a detailed listing of the analytical results. Results are reported in parts per billion (ng/mi.) for the analytes on an as-received basis.

6 Data/Sample Retention

Samples are disposed of one month after the report is issued unless otherwise specified. All electronic data is archived on retrievable media and hard copy reports are stored in data folders maintained by Exygen, Hardcopy data is stored for a minimum of five years. Occupational and Environmental Health will be notified 30 days prior to the disposal of hardcopy data.

- 7 Attachments
- 7.1 Attachment A: Chain of Custody
- 7.2 Attachment B: Analytical Results
- B Signatures

Frity F. Sector, Principal Investigator	7/29/04
Ently R. Becker, Principal Investigator	Date
Och M Flater T Sohn M. Flaherty, Vice President	7/29/104
John M. Fleherty, Viae President	Date

PAGE 4 OF 4

EID871404



3058 Research Drive State College, PA 16801

Phone: 814-272-1039 Fax: 814-231-1580

Login Group: L0003000

Login #: Project

3110 P0000959 Conform COC Sample: Conform COC: Conform Sample:

True True

Company Name: DuPont de Nemours & Co, Inc. Submitted By: Charles R. Powley

Charles R. Powley Immediate Receipt of Samples

Conform Request

True True

Login Type: Started: Date Start

Due Date: Received Date: 07/23/2004 08/06/2004 07/23/2004

Received By:

Ammerman, Mark

Spread Sample: Label: Exygen SD/PI:

Exygen SD/PI: Decker, Emily
Project Title/Type: Analysis for PFOA in Human Serum Samples by LC/MS/MS / ROUTINE

Login Notes: Conform Notes:

			Pac	kage	s / Container	\$				
Package	Carron	Mall Date	/ Condition		Shipper / ID		Temp	Control Temp.		Direction / Handled By
PK0003722	Package		3:38:30PM Uncompromised		FEDEX 8458 8093 4889			Dry Ica . · ;	•	RECEIVED Ammerman, Mark
Container # C0040828	Gross Weight 4.00 g	ън	Container Type 5 ml serum tube	٠	Preservative NONE			Mfa. Lot		Mta ID
C0040828 C0040829 C0040831	4.40 g 4.70 g 4.80 g	:	5 ml serum tube 5 ml serum tube 5 ml serum tube		NONE NONE	3	;			
C0040834 C0040838 C0040839	4.80 g 4.30 g 4.80 g		5 ml serum tube 5 ml serum tube 5 ml serum tube		NONE NONE					
C0040841 C0040843	4.60 g 5.00 g		5 ml serum tube 5 ml serum tube		NONE NONE			• • • • • • • • • • • • • • • • • • • •	·	
C0040844 C0040845 C0040848	4.80 g 5.30 g 4.00 g		5 mil serum tube 5 mil serum tube 5 mil serum tube		HONE HONE					

EID871405

7/29/04 Login.rpt Report Version: Jul 14 2004 11:35AM . Page 1 of 2

Instance: -

R0113316 IN THE PROPERTY OF THE PARTY OF

Login

				Sampl	les	P	The second secon	
Samole ID Lp003000-0001	Container C0040826	Matrix	Fraction Human Serum	Samola :		Date Samples 07/22/2004	Date Received 07/23/2004	Date Due 08/06/2004
	C0040828	LIQUID	Human Serum	:	CONFIDENTIAL	07/22/2004	07/23/2004	08/06/2004
L0003000-0003	C0040829	riouid	Human Sarum		INFORMATION	07/22/2004	07/23/2004	08/06/2004
L0003000-0004	C0040831	מוטסנו	Human Serum		REDACTED	07/22/2004	07/23/2004	08/06/2004
L0003000-000\$	C0040834	שוטסעו	Human Serum	1		07/22/2004	07/23/2004	06/06/2004
L0003000-0006	C0040836	חסטוס	Human Serum			07/22/2004	07/23/2004	08/05/2004
L0003000-0007	C0040639	חסשס	Human Sarum			07/22/2004	07/23/2004	08/05/2004
L0003000-0008	C0040841	LIQUID	Human Sarum	:		07/22/2004	07/23/2004	08/08/2004
L0003000-0000	C0040843	LIQUID	Human Serum			07/22/2004	07/23/2004	08/08/2004
L0003000-0010	C0040844	מוטפע	Human Serum			07/22/2004	07/23/2004	08/06/2004
L0003000-0011	C0040845	י ווסטוס	Human Serum	• •	, ;	• 07/22/2004	07/23/2004	08/06/2004
L0003000-0012	C0040848	משפט	Human Serum		· ·	07/22/2004	07/23/2004	08/06/2004

EID871406

7/29/04 Login.rpt Report Version: Jul 14 2004 11:35AM . Fage 2 of 2

Instance: '.

R0113316

CHAIN OF CUSTODY

ARCH

Evygen Research Sample Receiving • 3048 Research Drive • State College, PA 16801

1 814.231.8032 • www.exygenresearch.com FAX: 814.231.1580

	COLLECTION SITE INF	ORMATION	STAFF INVOLV	ED IN SAMPI	E SHIPMEN	T
	Collection Site (name & addre	53):	1. Logh Hor	Phinter		
	Dr. Morsha Po	aileu	(Printed Name)	D. L.	-300 m	1 22 011
	#4 Posemer	Once	Span	KULL	_OTY 1	1.50 CT
	Parkershura. 4	101JG VI	2. Terri la	Thevenin	-	
			grinted Narge)	V		i
			X Trans	Mounix		1.44.04
	Phone: 304-757	-0070	3.		8408	Voals
	Fax: 304-757-	091%	(Printed Name)			:.
	Email: Monileyneb	when 300 mt	Signathane			h/Daha
	IMPORTANT: Each person who	information on		ak name elemate		
	Ishara line and universal arrama	by Charifu AAA or PAA for	time entries Include m	and the throng	for dates Conto	intraf
	padage must be verified by sor prompt.(*) Thoroughly docum	neone other than the	ackager; attest to the	e verification by	Initialing and di	iting the
	and the time padaged by add	ling a footnote to the l	ottom of the page.	ume me serum pi	eparation is co	mpieted
		entification -	Blood Sang	ie Colect on Ser	um Sample Prep	Completed
			Annual Control of the	& Time	J · SSOA)	1:3500
			7.22.04	9:5500	J. D. AL	21520
CONFIDEN	ITIAL INFORMATION		7:2064	13'.20 Pm	7.20.04	1:562m
REDACTE	D		17.20.04	11:00am	7.2204	2:17 pm
			7.20.44	:10:45am	7.2004	1:547m
	1		7.30.44	10:00:01	7.2204	1:41 by
	-	9	J. 20 VA	12.0251	7.33.04	1:45247
	· .		7.000	10:25	1.2204	2:08 DW
	} -		7.250	11:2000	1.33-04	2:33 pm
	} -		7.20.00	1 8.10 cm	7.22.4	1:38pm
	} -		7.20.7	18.2000	7.20/4	1:30Pm
	-				1.77	- Lindy
		-				
		•				
		_				
		-				
٠						
	L					
	PLEASE FAX THE COMPLETED F prior to shipping samples.	ORM to Exygen Sample Rec	civing Cooler Con	tents Verified :	TLT	ग्रिश्च ०५
	KEEP THE PINK COPY and include the	ne other two with sample ship	ment Cooler ID #:_			
	Relinquished by	Date Time	Received by		Date:	
			11/		107 /27ky	Ma.
	Note: When samples arrive at Bygen, chain	-of-outbody procedures follow E	xygen SOP V401, "Contract F	Research Sample Handlin	g" Page	of]
	7,00,100					19/1.11/0

edix. USA Airbill 05d Krsmich Dr. dial braining + Iniological Association of the second 6984E6088548 1010 × VOIO! (irc)e THE DO - CHIEFE 944





Summary of Residue Found (ng/mL) for PFOA in Human Serum Samples

Spor	nsor	PFOA
	0	(ppb)
		• 103
1		103
	021	65.0
CONFIDENTIAL INFORM	ATION	15.7
		61.3
REDACTED		90.4
		86.4
10.79		8.03
		40.1
		128
		51,2
		83.1
*		73.7
		78.5
		42.6

EID871409

3058 Research Drive State College, PA 16801, USA T: 814.231.1580 exygencom





Summary of Recoveries (%) for PFOA in Human Serum Samples

•	Sponsor ID	PFOA ^ (ppb)	Amount Fartified (ppb)	Recovery (%)	
		5.10	5.0	102	
CONFIDENTIAL	INFORMATION	16.2	10	107	
		1040	. 1000	103	
REDACTED		1090	1000	99	•.
		4590	8000	90	••
			AVERAGE:	100	
•	\ ·		STD DEV:	6.4	
	\		% RSD:	6.4	

, :

Summary of RFOA (ng/mL) In Human Serum Control Samples

Sponsor ID	/.	PFOA (ng/mL)
Contro	IA \	5.47

EID871410

3058 Research Drive State Codega, PA 16801, USA T: 814.272.1039 F: 814.231.1580

Attachment 2



Terry OBryan 09/30/2004 11:37 AM To: Oscar Hernandez/DC/USEPA/US@EPA, Myra Karstadt/DC/USEPA/US@EPA

CC:

Subject: PFOA Serum Testing Data by Exygen Research

RAD has not yet received under TSCA 8(e) or voluntary FYI the Exygen Research report on PFOA human blood serum levels in West Virginia residents that was submitted on September 15, 2004 by Taft, Stettinius & Hollister LLP to Charles Auer for administrative record AR226. I specifically checked all recent DuPont submissions received by RAD. Also, a search of IMD's CBITS master tracking sytem of DuPont submissions since since July 29, 2004 showed only PMN-related documents for that time frame.